BlueCross BlueShield
Federal Employee Program

THALOMID
(thalidomide)

Pre - PA Allowance

None

Prior-Approval Requirements

Age 12 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Newly diagnosed multiple myeloma (MM)
    a. Used in combination with dexamethasone
2. Erythema nodosum leprosum (ENL) **AND ONE** of the following:
    a. Used for the acute treatment of the cutaneous manifestations of moderate to severe ENL
    b. Used as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL

AND ALL of the following:

a. Patient and prescriber must be enrolled and compliant with the **Thalomid REMS** program
b. Females of reproductive potential **only**: patient must have **TWO** negative pregnancy tests before initiating Thalomid
c. Females of reproductive potential **only**: patient will be advised to abstain continuously from heterosexual sexual intercourse or to use **TWO** methods of reliable birth control simultaneously for 4 weeks prior to initiation of Thalomid therapy, during therapy, during dose interruptions, and continuing for 4 weeks following the last dose
d. Males with female partners of reproductive potential **only**: patient will be advised to use a latex or synthetic condom during treatment with Thalomid and for 4 weeks after the last dose, even if they have undergone a successful vasectomy
e. Prescriber agrees to monitor for signs and symptoms of thromboembolism

Prior - Approval Limits

Quantity

Diagnosis	Dose Limit

BlueCross BlueShield
Federal Employee Program

THALOMID
(thalidomide)

Multiple myeloma (MM)	200 mg per day **OR**
Erythema nodosum leprosum (ENL)	400 mg per day

Duration 12 months

Prior – Approval *Renewal* Requirements

Age 12 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Multiple myeloma (MM)
    a. Used in combination with dexamethasone
    b. **NO** disease progression or unacceptable toxicity
2. Erythema nodosum leprosum (ENL) **AND ONE** of the following:
    a. Used for the acute treatment of the cutaneous manifestations of moderate to severe ENL
    b. Used as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL

AND ALL of the following:

a. Patient and prescriber must be enrolled and compliant with the **Thalomid REMS** program
b. Females of reproductive potential **only**: patient will be advised to abstain continuously from heterosexual sexual intercourse or to use **TWO** methods of reliable birth control simultaneously during therapy, during dose interruptions, and for 4 weeks after the last dose
c. Males with female partners of reproductive potential **only**: patient will be advised to use a latex or synthetic condom during treatment with Thalomid and for 4 weeks after the last dose, even if they have undergone a successful vasectomy
d. Prescriber agrees to monitor for signs and symptoms of thromboembolism

Prior - Approval *Renewal* Limits

Same as above